Daily Sepsis Research Analysis
Three studies advance sepsis science along mechanistic and clinical axes: endothelial CLEC5A is identified as a driver of vascular leakage and lung injury, RMP is shown to restrain TLR4–IKKβ/NF-κB signaling in macrophages, and estimated pulse wave velocity (ePWV) emerges as an independent predictor of 28-day mortality in sepsis-related AKI. Together, they reveal actionable targets for barrier stabilization, innate immune modulation, and pragmatic risk stratification.
Summary
Three studies advance sepsis science along mechanistic and clinical axes: endothelial CLEC5A is identified as a driver of vascular leakage and lung injury, RMP is shown to restrain TLR4–IKKβ/NF-κB signaling in macrophages, and estimated pulse wave velocity (ePWV) emerges as an independent predictor of 28-day mortality in sepsis-related AKI. Together, they reveal actionable targets for barrier stabilization, innate immune modulation, and pragmatic risk stratification.
Research Themes
- Endothelial barrier dysfunction and vascular leakage in sepsis
- Innate immune signaling control via IKKβ/NF-κB modulation
- Prognostic stratification using vascular stiffness (ePWV) in SA-AKI
Selected Articles
1. Endothelial CLEC5A drives barrier dysfunction and vascular leakage responsible for lung injury in bacterial pneumonia and sepsis.
Using murine CLP and LPS models, the authors show that endothelial CLEC5A causally drives inflammatory vascular leakage and mortality. Endothelial-specific CLEC5A knockdown improved survival, reversed by endothelial reexpression, and scRNA-seq revealed endothelial transcriptomic heterogeneity in CLEC5A-deficient lungs.
Impact: This work identifies endothelial CLEC5A as a tractable molecular driver of vascular barrier failure in sepsis, providing a concrete target for therapies aimed at preventing lung injury.
Clinical Implications: Therapeutic inhibition of endothelial CLEC5A could reduce vascular leakage and lung injury in bacterial pneumonia and sepsis; biomarker strategies might stratify patients with endothelial activation.
Key Findings
- Clec5a−/− mice exhibited decreased mortality after CLP-induced polymicrobial sepsis and LPS-induced endotoxemia.
- Endothelial-specific CLEC5A knockdown improved survival; endothelial reexpression abrogated this benefit, indicating endothelial causality.
- Single-cell RNA sequencing revealed transcriptomic heterogeneity among vascular endothelial cells in CLEC5A-deficient lungs after CLP.
- Protection was linked to attenuation of the inflammatory cytokine surge and reduced vascular leakage.
Methodological Strengths
- Endothelial cell–specific genetic manipulation with rescue experiments establishes cell-type causality.
- Use of both CLP sepsis and LPS endotoxemia models plus single-cell RNA-seq for mechanistic depth.
Limitations
- Findings are in murine models; human validation and pharmacologic targeting were not presented.
- The abstract does not detail specific human endothelial data or candidate inhibitors.
Future Directions: Develop selective CLEC5A antagonists or blocking antibodies with endothelial targeting, validate in human tissues and organoids, and assess efficacy in large-animal sepsis models.
Endothelial barrier dysfunction and the resulting vascular injury are responsible for multiorgan failure in sepsis. Myeloid C-type lectin domain family 5 member A (CLEC5A) is a pattern recognition receptor involved in host defense against infection. Mice lacking CLEC5A were resistant to cecal ligation and puncture (CLP)-induced polymicrobial sepsis and lipopolysaccharide (LPS)-induced endotoxemia, as observed by decreased mortality. Single-cell RNA sequencing revealed transcriptomic heterogeneity of vascular endothelial cells in CLEC5A-deficient lungs following CLP. Endothelial-specific knockdown of CLEC5A improved survival of CLP-challenged mice, which was completely ineffective with reexpression of endothelial CLEC5A. The survival benefits were attributed to alleviated inflammatory storm and vascular leakage. Furthermore, endothelial CLEC5A deficiency protected mice against
2. RNA polymerase II subunit 5-mediating protein limits TLR4-induced innate immune activation in macrophages by inhibiting IKKβ/NF-κB signaling during sepsis.
The study identifies RMP as a direct inhibitor of IKKβ within the IKK complex, recruiting PP2A to dampen NF-κB activation in macrophages. Under TLR4/LPS stimulation, RMP is phosphorylated by IKKβ yet functions to constrain innate immune activation, suggesting a therapeutic route to limit sepsis-related damage.
Impact: It uncovers a previously unappreciated brake on IKKβ/NF-κB signaling in macrophages, linking a defined molecular interaction to innate immune homeostasis in sepsis.
Clinical Implications: Targeting the RMP–IKKβ interaction or enhancing PP2A recruitment could attenuate excessive NF-κB–driven inflammation in sepsis without full immunosuppression.
Key Findings
- RMP directly binds the kinase domain of IKKβ and inhibits its activity by recruiting PP2A to the IKK complex.
- Upon TLR4/LPS stimulation, RMP is phosphorylated by IKKβ but acts to limit NF-κB activation in macrophages.
- Genetic manipulation of RMP in mice demonstrated modulation of NF-κB signaling and suggested attenuation of sepsis-related damage.
Methodological Strengths
- Mechanistic biochemistry mapping direct protein–protein interaction and phospho-regulation within the IKK complex.
- Use of transgenic mouse strains and macrophage models to link molecular mechanism to in vivo inflammatory responses.
Limitations
- Specific phosphorylation site details and comprehensive in vivo sepsis outcome metrics are not fully described in the abstract.
- No human validation or pharmacologic modulation of the RMP–IKKβ axis is presented.
Future Directions: Define the exact phosphorylation sites and dynamics of RMP, assess small-molecule or peptide modulators of the RMP–IKKβ interface, and validate translational relevance in human macrophages and tissues.
BACKGROUND: Nuclear factor κB (NF-κB) activity is a central component of inflammatory and innate immune responses, which plays a crucial role in sepsis. The inhibition of NF-κB signaling and the IκB kinase (IKK) complex is important for understanding the control of innate immunity and regulating the progress of sepsis. METHODS: We constructed transgenic mouse strains (Rmp RESULTS: We identified RNA polymerase II subunit 5 (RPB5)-mediating protein (RMP) as an inhibitor of the IKK complex, which thus inhibited NF-κB signaling in macrophages. In resting macrophages, RMP was directly bound to the kinase domain of IKKβ and inhibited its activity by recruiting protein phosphatase 2 A (PP2A) to the IKK complex. When mouse macrophages were treated with LPS, a Toll-like receptor 4 (TLR4) agonist that stimulates NF-κB signaling, RMP was phosphorylated by IKKβ at Ser CONCLUSIONS: RMP inhibits TLR4-induced NF-κB activation and exerts homeostatic control of innate immunity, and may be promising as a therapeutic target in the limiting of NF-κB signaling and attenuating sepsis-related damage.
3. The relationship between estimated pulse wave velocity and 28-day mortality in patients with sA-AKI: a retrospective cohort analysis of the MIMIC-IV database.
In 16,514 ICU patients with sepsis-associated AKI, higher ePWV (>10.535 m/s) was associated with worse 28-day survival. Adjusted Cox models and restricted cubic spline analysis supported an independent and dose-responsive relationship, consistent across subgroups.
Impact: This large, well-analyzed cohort introduces a simple arterial stiffness surrogate (ePWV) as a pragmatic, independent predictor of short-term mortality in SA-AKI.
Clinical Implications: ePWV can aid early risk stratification in SA-AKI, potentially guiding monitoring intensity, hemodynamic targets, and discussions about prognosis.
Key Findings
- Among 16,514 SA-AKI patients, those with high ePWV (>10.535 m/s) had significantly poorer 28-day survival by Kaplan–Meier analysis.
- Cox proportional hazards models showed ePWV remained an independent predictor of 28-day mortality after adjustment for confounders.
- Restricted cubic spline analyses suggested a dose-response relationship between increasing ePWV and higher mortality risk, with consistent effects across subgroups.
Methodological Strengths
- Large sample size with robust multivariable modeling and restricted cubic spline to assess nonlinearity.
- Predefined ROC-based thresholding and subgroup stratified analyses enhance interpretability and generalizability.
Limitations
- Retrospective single-database analysis with potential residual confounding; ePWV is an estimate rather than direct measurement.
- Lack of external validation outside MIMIC and absence of intervention data linking ePWV modification to outcomes.
Future Directions: Prospective multicenter validation, integration of direct PWV measurements, and trials testing whether modifying arterial stiffness or hemodynamics improves outcomes in SA-AKI.
BACKGROUND: Acute kidney injury (AKI) is a common and serious complication in critically ill patients, especially those with sepsis. Recent studies suggest that estimated pulse wave velocity (ePWV) is an independent prognostic factor for in-hospital mortality in AKI patients. The objective of this research is to examine the correlation between ePWV and 28-day mortality among patients with sepsis-related acute kidney injury (SA-AKI). METHODS: This retrospective cohort study utilized data from 16,514 patients with SA-AKI in the MIMIC-IV database. ePWV was categorized based on the ROC curve cutoff value, dividing patients into two groups: high (>10.535 m/s) and low (≤10.535 m/s). To compare survival outcomes between the groups, Kaplan-Meier survival analysis was conducted. Cox proportional hazards models were used to assess the association between ePWV and 28-day mortality, adjusting for potential confounders. Additionally, a restricted cubic spline (RCS) model was employed to explore a possible dose-response relationship. Stratified analyses were conducted to examine the effect of ePWV on 28-day mortality across different subgroups. RESULTS: Survival analysis revealed that individuals with high ePWV experienced poorer 28-day survival outcomes compared to those with low ePWV. After adjusting for confounding factors, ePWV continued to be a predictive factor for 28-day mortality in patients with SA-AKI ( CONCLUSION: ePWV serves as an independent predictor of 28-day mortality in patients with SA-AKI. This metric offers prognostic insights to help clinicians identify high-risk patients early, enabling timely interventions and better clinical outcomes.